Journal ArticleDOI
Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists
Nico De Crem,Kathelijne Peerlinck,Thomas Vanassche,Kristine Vanheule,Barbara Debaveye,Saskia Middeldorp,Peter Verhamme,Marijke Peetermans +7 more
Reads0
Chats0
TLDR
AUB is frequent after initiation of anticoagulant therapy for acute symptomatic VTE patients of reproductive age and compared to VKAs, rivaroxaban was associated with prolonged menstrual bleeding and more medical interventions and adaptation of anti-cancer treatment.About:
This article is published in Thrombosis Research.The article was published on 2015-10-01. It has received 77 citations till now. The article focuses on the topics: Rivaroxaban & Vitamin K antagonist.read more
Citations
More filters
Journal ArticleDOI
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
Jan Steffel,Peter Verhamme,Tatjana S. Potpara,Pierre Albaladejo,M Antz,Lien Desteghe,Karl Georg Haeusler,Jonas Oldgren,Holger Reinecke,Roldan-Schilling,Nigel Rowell,Peter Sinnaeve,Ronan Collins,Alan John Camm,Hein Heidbuchel +14 more
TL;DR: Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with atrial fibrillation (AF) and have emerged as the preferred choice, particularly in patients newly started on antICOagulation.
Journal ArticleDOI
The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions.
TL;DR: The International Federation of Gynecology and Obstetrics (FIGO) systems for nomenclature of symptoms of normal and abnormal uterine bleeding in the reproductive years and for classification of causes of AUB were published together in 2011 to facilitate research, education, and clinical care.
Journal ArticleDOI
Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use.
Ida Martinelli,Anthonie W. A. Lensing,Saskia Middeldorp,Marcel Levi,Jan Beyer-Westendorf,Bonno van Bellen,Henri Bounameaux,Timothy A. Brighton,A.T. Cohen,Mila Trajanovic,Martin Gebel,Phuong Lam,Philip S. Wells,Martin H. Prins +13 more
TL;DR: In this article, the authors compared the use of hormonal therapy, especially those containing estrogens, is associated with recurrent venous thromboembolism (VTE) during anticoagulation.
Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use Running head: Recurrent VTE and abnormal uterine bleeding
Ida Martinelli,Saskia Middeldorp,Marcel Levi,Jan Beyer,Bonno van Bellen,Henri Bounameaux,Timothy A. Brighton,Mila Trajanovic,Martin Gebel,Ho Chi Minh +9 more
TL;DR: Hormonal therapy was not associated with an increased risk of recurrent VTE in women receiving therapeutic anticoagulation and the observed increasedrisk of abnormal uterine bleeding with rivaroxaban needs further exploration.
Journal ArticleDOI
Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
Marjolein P. A. Brekelmans,Luuk J. J. Scheres,Suzanne M. Bleker,Barbara A. Hutten,Anne Timmermans,Harry R. Büller,Saskia Middeldorp +6 more
TL;DR: Although the absolute number of vaginal bleeding events is comparable between apixaban and enoxaparin/warfarin recipients, the relative occurrence of vaginal bleeds is higher in apixaba-treated women.
References
More filters
Journal ArticleDOI
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel,Kenneth W. Mahaffey,Jyotsna Garg,Guohua Pan,Daniel E. Singer,Werner Hacke,Günter Breithardt,Jonathan L. Halperin,Graeme J. Hankey,Jonathan P. Piccini,Richard C. Becker,Christopher C. Nessel,John F. Paolini,Scott D. Berkowitz,Robert M. Califf +14 more
TL;DR: In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism and there was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivroxaban group.
Journal ArticleDOI
Oral rivaroxaban for symptomatic venous thromboembolism
Rupert Bauersachs,Scott D. Berkowitz,Benjamin Brenner,Harry R. Buller,Hervé Decousus,Alexander Gallus,Anthonie W. A. Lensing,Frank Misselwitz,Martin H. Prins,Gary E. Raskob,Annelise Segers,Peter Verhamme,Phil Wells,Giancarlo Agnelli,Henri Bounameaux,Alexander T. Cohen,Bruce L. Davidson,Franco Piovella,Sebastian Schellong +18 more
TL;DR: Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation.
Journal ArticleDOI
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Barry F. Jacobson,Erich Minar,Jaromir Chlumsky,Peter Verhamme,Phil Wells,Giancarlo Agnelli,Alexander T. Cohen,Scott D. Berkowitz,Bruce L. Davidson,Frank Misselwitz,Gary E. Raskob,Annelise Segers +11 more
TL;DR: A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefit-risk profile.
Journal ArticleDOI
Derivation of a Simple Clinical Model to Categorize Patients Probability of Pulmonary Embolism: Increasing the Models Utility with the SimpliRED D-dimer
Philip S. Wells,David Anderson,Marc A. Rodger,Jeffrey S. Ginsberg,Clive Kearon,Michael Gent,Alexander G.G. Turpie,Janis Bormanis,Jeffrey I. Weitz,Michael Chamberlain,Dennis Bowie,David Barnes,Jack Hirsh +12 more
TL;DR: The combination of a score < or =4.0 by the authors' simple clinical prediction rule and a negative SimpliRED D-Dimer result may safely exclude PE in a large proportion of patients with suspected PE.
Journal ArticleDOI
Value of assessment of pretest probability of deep-vein thrombosis in clinical management
Philip S. Wells,David Anderson,Janis Bormanis,Fred Guy,Michael Mitchell,Lisa Gray,Cathy Clement,K Sue Robinson,Bernard Lewandowski +8 more
TL;DR: Management of patients with suspected deep-vein thrombosis based on clinical probability and ultrasound of the proximal deep veins is safe and feasible and the need for serial ultrasound testing is reduced and the rate of false-negative or false-positive ultrasound studies is reduced.
Related Papers (5)
Oral rivaroxaban for symptomatic venous thromboembolism
Rupert Bauersachs,Scott D. Berkowitz,Benjamin Brenner,Harry R. Buller,Hervé Decousus,Alexander Gallus,Anthonie W. A. Lensing,Frank Misselwitz,Martin H. Prins,Gary E. Raskob,Annelise Segers,Peter Verhamme,Phil Wells,Giancarlo Agnelli,Henri Bounameaux,Alexander T. Cohen,Bruce L. Davidson,Franco Piovella,Sebastian Schellong +18 more